Compare

BPC-157 vs TB-500

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

99 users report co-tracking this pair (4% of BPC-157 trackers also track TB-500).

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

BPC-157

2443 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 18% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-158
Appetite control
-32
Energy
-84
Mood
0
Focus
-102

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-62
GI discomfort
-133
Dizziness
-119
Fatigue
-5
Nausea
-103

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05–5 mg

0.05–0.1 mg
4
0.1–0.2 mg
7
0.2–0.4 mg
12
0.4–0.6 mg
22
0.6–1 mg
31
1–2 mg
20
2–3 mg
11
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing47stacking15side effects33bpc-15726

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 33 days · Based on 537 repeat reporters

TB-500

486 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 26% · Unfavorable overall 14%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
-43
Lean mass
-153
Joint comfort
-144
Recovery
-98
Digestive comfort
-47

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-127
Appetite loss
-73
Injection site reaction
1
Anxiety
-102
Flushing
-48

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
8
0.2–0.4 mg
16
0.4–0.6 mg
19
0.6–1 mg
14
1–2 mg
4

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing50stacking38side effects26tb-50019

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 107 repeat reporters

Sources (15)

Published sources linked on the BPC-157 and TB-500 wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

    Chang CH, Tsai WC, Lin MS, et al. Molecules. 2019

    Source
    Wiki study page →
  3. PubMed

    BPC 157 and its role in accelerating wound healing

    Vukojevic J, Siroglavic M, Kasnik K, et al. Int J Mol Sci. 2022

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    BPC-157 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  5. PubMed

    BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing

    Seiwerth S, Rucman R, Turkovic B, et al. Current pharmaceutical design. 2018

    Source
    Wiki study page →
  6. PubMed

    Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions

    Ilic S, Drmic D, Franjic S, et al. Life sciences. 2011

    Source
    Wiki study page →
  7. PubMed

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B. Altern Ther Health Med. 2021

    Source
    Wiki study page →
  8. PubMed

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

    Yuan C, Demers A, Silva-Ortiz V, et al. Int J Mol Sci. 2026

    Source
    Wiki study page →
  9. PubMed

    Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians

    Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026

    Source
    Wiki study page →
  10. PubMed

    Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

    Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026

    Source
    Wiki study page →
  11. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  12. PubMed

    Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart

    Smart N, Riley PR. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  13. ClinicalTrials.gov

    Thymosin beta-4 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  14. PubMed

    Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

    Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012

    Source
    Wiki study page →
  15. PubMed

    Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing

    Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007

    Source
    Wiki study page →